Paraganglioma Global Market Report 2025

The paraganglioma market size has grown strongly in recent years. It will grow from $2.89 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to advancements in diagnostic imaging, increased awareness and screening programs, regulatory approvals for targeted therapies, the expansion of specialized treatment centers, and progress in genetic testing.

The paraganglioma market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to emerging targeted therapies and immunotherapies, the expansion of radiopharmaceuticals, the rising prevalence of genetic diseases, increasing investments in rare disease research, and improved healthcare access in emerging markets. Major trends expected during this period include advancements in targeted therapies, the expansion of radiopharmaceuticals, the rise of immunotherapy approaches, enhanced use of artificial intelligence (AI) in diagnostics, and the development of minimally invasive surgical techniques.

The growing investments in oncology research and medicine are expected to drive the expansion of the paraganglioma market in the coming years. Investments in oncology research and medicine refer to financial commitments made by governments, pharmaceutical companies, research institutions, and private investors to advance cancer prevention, diagnosis, and treatment. The increase in such investments is fueled by the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expansion of clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. These investments support advancements in paraganglioma by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to better understand the disease’s biology and progression. For instance, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, the increasing investments in oncology research and medicine are fueling the growth of the paraganglioma market.

Leading companies in the paraganglioma market are prioritizing the development of advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors to provide targeted treatment options for patients. An oral HIF-2α inhibitor is a targeted therapy that inhibits HIF-2α activity, a key factor in tumor growth under low-oxygen conditions, thereby slowing cancer progression in conditions such as paraganglioma. For example, in January 2025, Merck, a US-based biopharmaceutical company, announced that its supplemental new drug application for Welireg (belzutifan) received priority review from the U.S. Food and Drug Administration (FDA), a US-based government agency. Welireg is intended for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The supplemental new drug application (sNDA) is supported by objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.

In January 2022, Exact Sciences Corp., a US-based molecular diagnostics company, acquired PreventionGenetics for an undisclosed amount. This acquisition was aimed at expanding Exact Sciences' hereditary cancer testing capabilities, increasing access to early detection and personalized treatment options. PreventionGenetics, a US-based clinical genetic testing laboratory, specializes in genetic testing for hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome.

Major players in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome, National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John’s Cancer Institute.

North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paraganglioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paraganglioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Paraganglioma is a rare neuroendocrine tumor that arises from paraganglia, clusters of cells associated with the autonomic nervous system. These tumors are typically found in the head, neck, chest, or abdomen and may produce excess hormones, posing a risk of malignancy. Early diagnosis is crucial for effective management and preventing complications.

The main types of paraganglioma include sympathetic, parasympathetic, carotid, cervical, jugular, secretory, and temporal paragangliomas. Sympathetic paragangliomas, which develop in the sympathetic nervous system, often produce catecholamines. These tumors originate from various locations, such as the head and neck, abdomen, pelvis, and other areas. Treatment options include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and other approaches. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, catering to end-users such as hospitals, specialty clinics, and cancer research institutes.

The paraganglioma market research report is one of a series of new reports that provides paraganglioma market statistics, including the paraganglioma industry global market size, regional shares, competitors with the paraganglioma market share, detailed paraganglioma market segments, market trends, and opportunities, and any further data you may need to thrive in the paraganglioma industry. This paraganglioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.